

MEDIVIR AB, Outperform, Monetizing Cold Sores to Focus On Improved Protease Inhibitors for HCV Treatment.

<https://marketpublishers.com/r/M21C1985056EN.html>

Date: June 2011

Pages: 2

Price: US\$ 90.00 (Single User License)

ID: M21C1985056EN

Abstracts

Medivir's Xerese fetched \$45m for the company from Meda AB for US, Canada and Mexico rights. Improved cash position would help MVIR concentrate more on its pipeline and in licensing opportunities. TMC435 (Protease Inhibitor, PhII/III, partnered with Tibotec/JNJ) could offer compelling advantage over currently approved PIs and remains the key driver MVIR. For more detail, please read our report released on 29th June on MVIR titled "Monetizing Cold Sores to Focus On Improved Protease Inhibitors for HCV Treatment" and Initiation report released on 24th June titled "Next in HCV- A Once Daily Protease Inhibitor Option".

Contents

COMPANIES MENTIONED

MEDIVIR AB, MVIR,

I would like to order

Product name: MEDIVIR AB, Outperform, Monetizing Cold Sores to Focus On Improved Protease Inhibitors for HCV Treatment.

Product link: <https://marketpublishers.com/r/M21C1985056EN.html>

Price: US\$ 90.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M21C1985056EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

